Publication
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugRadiation Therapycivic_curation1.00
- drugTaselisibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- genePTENcivic_curation1.00
- variantPIK3CA Amplificationcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPTEN Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26589432
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA Amplification1 | ||||||||
| Taselisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID1464The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PIK3CA H1047R1 | ||||||||
| Taselisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1465The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib conc… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PIK3CA Mutation1 | ||||||||
| Radiation Therapy + TaselisibCombination | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1490A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensiti… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PTEN Mutation1 | ||||||||
| Taselisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | 3 | accepted | EID1467In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably … (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |